Taking into account the well-known role of the KEAP1/NRF2 pathway in chemotherapy resistance, pharmacological tests were also performed to investigate whether KEAP1 suppression had an impact on SCLC as a molecular marker to predict tumor cell response to cisplatin and etoposide agents. The gene discussed is NFE2L2; the disease is small cell lung carcinoma.